Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuphoria Therapeutics (NEUP) Depreciation & Amortization (CF) (2024 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed Depreciation & Amortization (CF) for 2 consecutive years, with $165789.0 as the latest value for Q4 2025.

  • Quarterly Depreciation & Amortization (CF) changed 0.2% to $165789.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $662637.0 through Dec 2025, up 99.69% year-over-year, with the annual reading at $662890.0 for FY2025, 0.02% changed from the prior year.
  • Depreciation & Amortization (CF) for Q4 2025 was $165789.0 at Neuphoria Therapeutics, roughly flat from $165792.0 in the prior quarter.
  • The five-year high for Depreciation & Amortization (CF) was $166121.0 in Q4 2024, with the low at $165431.0 in Q1 2025.